A multicenter clinical trial investigates the efficacy of a newly developed monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with familial hypercholesterolemia. A total of 4,000 patients are enrolled and randomly assigned in equal numbers to receive either the monoclonal antibody or a placebo injection every two weeks. All participants remain on their maximally tolerated statin therapy. Over a 3-year follow-up period, a nonfatal myocardial infarction occurs in 100 of the 2,000 patients in the treatment group, compared to 150 of the 2,000 patients in the placebo group. Based on these findings, what is the number needed to treat (NNT) to prevent one nonfatal myocardial infarction over the 3-year period?
Cevap: 40 patients